You are here

Home » Publications

Cancer Program

Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.
Tsvetkov P, Sokol E, Jin D, et al. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A. 2017;114(2):382-387. doi:10.1073/pnas.1619067114.
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. doi:10.1038/ncomms11589.
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.
Holst F, Hoivik EA, Gibson WJ, et al. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016;6:25521. doi:10.1038/srep25521.
Characterizing genomic alterations in cancer by complementary functional associations.
Kim JWook, Botvinnik OB, Abudayyeh O, et al. Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016;34(5):539-46. doi:10.1038/nbt.3527.
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8. doi:10.1126/science.aad5214.
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK, Schenone M, Ferreira MVentura, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22(3):288-97. doi:10.1038/nm.4047.
Targeting MTHFD2 in acute myeloid leukemia.
Pikman Y, Puissant A, Alexe G, et al. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016;213(7):1285-306. doi:10.1084/jem.20151574.
Integrated genetic and pharmacologic interrogation of rare cancers.
Hong AL, Tseng Y-Y, Cowley GS, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016;7:11987. doi:10.1038/ncomms11987.
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAP kinase pathway mutations.
Louissaint A, Schafernak KT, Geyer J, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAP kinase pathway mutations. Blood. 2016. doi:10.1182/blood-2015-12-682591.
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-6. doi:10.1038/ng.3557.
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48(6):607-16. doi:10.1038/ng.3564.
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
Kim E, Ilic N, Shrestha Y, et al. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016;6(7):714-26. doi:10.1158/2159-8290.CD-16-0160.
Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.
Haradhvala NJ, Polak P, Stojanov P, et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell. 2016;164(3):538-49. doi:10.1016/j.cell.2015.12.050.
Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers.
Zhang X, Choi PS, Francis JM, et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016;48(2):176-82. doi:10.1038/ng.3470.
Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016;14(2):207-15. doi:10.1158/1541-7786.MCR-15-0321.
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.
de Waal L, Lewis TA, Rees MG, et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016;12(2):102-8. doi:10.1038/nchembio.1984.
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.
Aguirre AJ, Meyers RM, Weir BA, et al. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016;6(8):914-29. doi:10.1158/2159-8290.CD-16-0154.
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189-96. doi:10.1126/science.aad0501.
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.
Puram RV, Kowalczyk MS, de Boer CG, et al. Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell. 2016;165(2):303-16. doi:10.1016/j.cell.2016.03.015.
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.
Yu C, Mannan AM, Yvone GMetta, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016;34(4):419-23. doi:10.1038/nbt.3460.
Comprehensive assessment of cancer missense mutation clustering in protein structures.
Kamburov A, Lawrence MS, Polak P, et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A. 2015;112(40):E5486-95. doi:10.1073/pnas.1516373112.
TERT promoter mutations and monoallelic activation of TERT in cancer.
Huang FW, Bielski CM, Rinne ML, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015;4:e176. doi:10.1038/oncsis.2015.39.
Pharmacogenomic agreement between two cancer cell line data sets.
Pharmacogenomic agreement between two cancer cell line data sets. Nature. 2015;528(7580):84-7. doi:10.1038/nature15736.